Effect of Finerenone on CKD outcomes in T2DM

Finerenone decreased risk of CKD progression by 18%

Finerenone decreased CV morbidity & mortality by 14%

Published in @NEJM today

https://www.nejm.org/doi/full/10.1056/NEJMoa2025845?query=RP

@ASNKidney #Kidneywk

How does Finerenone work?
(These Slides are from the ASN Kidney Week: High Impact Clinical Trial Session)

Trial eligibility criteria

Study Design

Baseline Demographics & Medications

Baseline eGFR and UACR

Change in UACR: 31% reduction with Finerenone at 4 months versus placebo

BP and HbA1c changes in the Finerenone and placebo groups

18% reduction in the Primary Kidney Composite Endpoint in the
Finerenone group versus the Placebo group (p = 0.0014)

Numbers Needed to Treat (NNT)
for Primary and Secondary endpoints over 3 years

Adverse Events and Change in Serum Potassium over time

Adverse events related to Hyperkalemia such as permanent drug discontinuation, hospitalization and death

Adverse events related to Acute Kidney Injury

Safety Summary of Finerenone

How drug discontinuation due to Hyperkalemia in FIDELIO-DKD Trial compare to the ALTITUDE & VA-NEPHRON-D Trials where dual RAS Blockade was used in DKD populations?

How did drug discontinuation due to Hyperkalemia in FIDELIO-DKD Trial compare to the AMBER Trial where Patiromer was used with Spironolactone + ACEi/ARB in CKD population?

FIDELIO-DKD Trial Conclusions
#FIDELIODKD